Oral GLP-1 · a non-peptide medicine
Foundayo prices change with tablet strength and offer dates. Compare manufacturer medication pricing with the additional cost of telehealth care.
Inspect the terms, then compare
Sorting compares displayed numbers only. Billing units, routes, supply periods and included services can differ. Featured placements above are separate.
Listed medication $149/month plus standard ongoing membership $149/month. Membership is $39 in the first month. Manufacturer eligibility, strength and refill conditions still apply.
Regular listed price. Manufacturer eligibility restrictions apply, and additional taxes or fees may apply. A prescribing visit is a separate consideration.
Temporarily $149 through December 31, 2026; regular price $199. Manufacturer eligibility restrictions apply, and additional taxes or fees may apply. A prescribing visit is a separate consideration.
Temporarily $199 through December 31, 2026; regular price $299. Manufacturer eligibility restrictions apply, and additional taxes or fees may apply. A prescribing visit is a separate consideration.
Regular listed price. Manufacturer eligibility restrictions apply, and additional taxes or fees may apply. A prescribing visit is a separate consideration.
Purchase offer requires timely refills within 45 days; regular price $349. Manufacturer eligibility restrictions apply, and additional taxes or fees may apply. A prescribing visit is a separate consideration.
No matching offers. Try another filter.
FDA approved Foundayo (orforglipron) on April 1, 2026 for certain adults with obesity or overweight with a weight-related condition, alongside diet and physical activity. Orforglipron is a non-peptide small molecule; we include it as a related GLP-1 option. Approval of Foundayo does not confer approval on a compounded version.
Sources: FDA — Foundayo approval, April 1, 2026, Lilly — Foundayo self-pay and savings terms
Follow the evidence
Checked October 8, 2026. Provider pages document advertised terms; they do not independently establish clinical outcomes.
Approval and indicated population; a non-peptide GLP-1 medicine.
Official public information; price and terms checked October 8, 2026.
Official public information; price and terms checked October 8, 2026.